Word: directors
(lookup in dictionary)
(lookup stats)
Dates: all
Sort By: most recent first
(reverse)
...what could have been a fresh franchise? Start this group off as freshmen and keep them that way for the duration of the film? Then you've got Fame 2, and maybe in Fame 3 we'd get to see Frasier and Lilith reunite, and bingo: first-time feature director Kevin Tancharoen, making his crossover from the world of choreography, has a whole new career. As it is, the years whip by far too quickly. "Already?" the woman behind me said plaintively when the words "Sophomore Year" flashed up on the screen. That's the joy of this Fame. Like...
Since Sept. 8, chairman and chief executive Robert Toll has unloaded more than 4.3 million shares and pocketed at least $82.5 million in pretax net proceeds, according to filings with the Securities and Exchange Commission. At least two other insiders - director Bruce Toll and president Zvi Barzilay - have also been selling: Bruce Toll sold 352,433 shares, netting proceeds of about $7.5 million, while Barzilay dumped 200,000 shares for net proceeds of about $3.5 million, the filings reported. In some but not all cases, the insiders sold shares they had acquired through stock options that were to expire...
Robert Toll "has been an astute investor and has opportunistically sold stock" in the past, says Bob Curran, managing director at Fitch Ratings. "Many have suggested that they think the [homebuilding] stocks might be ahead of themselves." (See pictures of Americans in their homes...
Still, many analysts believe the 2009 stock run-up among homebuilders has gotten ahead of the sector's pending recovery. "The stocks have gone too far, too fast," says Rob Stevenson, managing director at Fox-Pitt Cochran Caronia. Stevenson isn't surprised by the insider selling at Toll Brothers: "We think the group has gotten overvalued and that a pullback is likely." After all, he notes, "they're still not producing a profit...
...efficacy is a modest one. But it's the first time we've seen a positive signal of efficacy in a human trial of any HIV vaccine. That's an exciting result in a field that has been characterized by disappointments for two decades," says Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases (NIAID), which provided major funding and other support for the Thai trial...